Genitope (GTOP) To Suspend MyVax Development
Genitope Corporation (NASDAQ: GTOP) said based on a meeting with representatives of the FDA to discuss the previously announced results of Genitope’s pivotal Phase 3 clinical trial of MyVax personalized immunotherapy in previously untreated follicular B-cell non-Hodgkin’s lymphoma patients, Genitope intends to suspend development of MyVax personalized immunotherapy. Genitope is evaluating its alternatives with respect to the other aspects of its business, including development of its monoclonal antibody program.
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Cepheid (CPHD) Receives FDA Approval for GeneXpert Infinity-80 System
- Sucampo Pharma (SCMP) Updates on Protective Effect of SPI-8811 in NSAID-Induced GMI
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
